ZYLOX-TONBRDG.MED.TECH.H1 (818) - Total Liabilities
Based on the latest financial reports, ZYLOX-TONBRDG.MED.TECH.H1 (818) has total liabilities worth €341.97 Million EUR (≈ $399.80 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 818 shareholders equity momentum to track the company's year-over-year net asset growth rate.
ZYLOX-TONBRDG.MED.TECH.H1 - Total Liabilities Trend (2021–2024)
This chart illustrates how ZYLOX-TONBRDG.MED.TECH.H1's total liabilities have evolved over time, based on quarterly financial data.
ZYLOX-TONBRDG.MED.TECH.H1 Competitors by Total Liabilities
The table below lists competitors of ZYLOX-TONBRDG.MED.TECH.H1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ChengDa Pharmaceuticals Co. Ltd.
SHE:301201
|
China | CN¥249.97 Million |
|
Harim Holdings Co. Ltd
KQ:003380
|
Korea | ₩10.68 Trillion |
|
Van Phu - Invest Investment JSC
VN:VPI
|
Vietnam | ₫9.25 Trillion |
|
Mid Penn Bancorp
NASDAQ:MPB
|
USA | $5.32 Billion |
|
Sinosteel Luonai Materials Technology Co. Ltd. A
SHG:688119
|
China | CN¥2.03 Billion |
|
Chongqing Constr Engineering
SHG:600939
|
China | CN¥77.72 Billion |
|
Nuh Cimento Sanayi AS
IS:NUHCM
|
Turkey | TL4.16 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down ZYLOX-TONBRDG.MED.TECH.H1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ZYLOX-TONBRDG.MED.TECH.H1 (818) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ZYLOX-TONBRDG.MED.TECH.H1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ZYLOX-TONBRDG.MED.TECH.H1 (2021–2024)
The table below shows the annual total liabilities of ZYLOX-TONBRDG.MED.TECH.H1 from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €351.56 Million ≈ $411.01 Million |
+7.08% |
| 2023-12-31 | €328.32 Million ≈ $383.84 Million |
+105.79% |
| 2022-12-31 | €159.54 Million ≈ $186.52 Million |
+53.98% |
| 2021-12-31 | €103.61 Million ≈ $121.13 Million |
-- |
About ZYLOX-TONBRDG.MED.TECH.H1
Zylox-Tonbridge Medical Technology Co., Ltd., a medical device company, provides neuro- and peripheral-vascular interventional medical devices in the People's Republic of China and internationally. The company offers a neurovascular product portfolio that covers a suite of products for various categories, including ischemic stroke, hemorrhagic stroke, intracranial stenosis, carotid artery, and in… Read more